Association between early hyperoxia exposure after resuscitation from cardiac arrest and neurological disability: A prospective multi-center protocol-directed cohort study

Brian W. Roberts, MD1, J. Hope Kilgannon, MD1, Benton R. Hunter, MD3, Michael A. Puskarich, MD4, Lisa Pierce, BA2, Michael Donnino, MD5, Marion Leary, RN, MPH, MSN6, Jeffrey A. Kline, MD3, Alan E. Jones, MD4, Nathan I. Shapiro, MD, MPH5, Benjamin S. Abella, MD, MPhil6, and Stephen Trzeciak, MD, MPH1,2

1The Department of Emergency Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey
2The Department of Medicine, Division of Critical Care Medicine, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey
3The Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana
4The Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi
5The Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
6The Center for Resuscitation Science and Department of Emergency Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Abstract

Background—Studies examining the association between hyperoxia exposure after resuscitation from cardiac arrest and clinical outcomes have reported conflicting results. Our objective was to test the hypothesis that early post-resuscitation hyperoxia is associated with poor neurological outcome.

Methods—Multi-center, prospective cohort study. We included adult, cardiac arrest patients who were mechanically ventilated and received targeted temperature management after return of spontaneous circulation (ROSC). We excluded patients with cardiac arrest due to trauma or sepsis. Per protocol, partial pressure of arterial oxygen (PaO₂) was measured at one and six hours after ROSC. Hyperoxia was defined as a PaO₂ > 300 mmHg during the initial six hours after ROSC. The primary outcome was poor neurological function at hospital discharge, defined as a modified Rankin Scale > 3. Multivariable generalized linear regression with a log link was used to test the association between PaO₂ and poor neurological outcome. To assess if there was an association

Address for correspondence: Stephen Trzeciak, MD, MPH, Cooper University Hospital, One Cooper Plaza, D428, Camden, New Jersey 08103, Phone: (856) 342-3342, trzeciak-stephen@cooperhealth.edu.

Disclosures: None of the authors have potential financial conflicts of interest to disclose.
between other supranormal PaO\textsubscript{2} levels and poor neurological outcome, we used other PaO\textsubscript{2} cut points to define hyperoxia (i.e. 100, 150, 200, 250, 350, 400 mmHg).

**Results**—Of the 280 patients included, 105 (38\%) had exposure to hyperoxia. Poor neurological function at hospital discharge occurred in 70\% of patients in the entire cohort, and 77\% vs. 65\% among patients with and without exposure to hyperoxia respectively [absolute risk difference 12\% (95\% CI 1\% – 23\%)]. Hyperoxia was independently associated with poor neurological function, relative risk 1.23 (95\% CI 1.11 - 1.35). On multivariable analysis, a one-hour longer duration of hyperoxia exposure was associated with a 3\% increase in risk of poor neurological outcome [relative risk 1.03 (95\% CI 1.02 - 1.05)]. We found the association with poor neurological outcome began at 300 mmHg or higher.

**Conclusions**—Early hyperoxia exposure after resuscitation from cardiac arrest was independently associated with poor neurological function at hospital discharge.

**Keywords**
Hyperoxia; cardiac arrest; neurological injury; brain injury; partial pressure of arterial oxygen

**Introduction**

Post-cardiac arrest syndrome is a unique pathophysiological condition characterized by systemic post-resuscitation ischemia/reperfusion injury commonly resulting in neurological damage.\textsuperscript{1,2} The in-hospital mortality among individuals with post-cardiac arrest syndrome is over 50\%, and among those that survive, many are left with permanent and severe neurological disability.\textsuperscript{3} The identification of new therapies to attenuate the ongoing brain injury in this patient population is of the utmost importance given that cardiac arrest occurs in over 400,000 people each year in the United States alone.\textsuperscript{4}

Exposure to hyperoxia [supranormal partial pressure of arterial oxygen (PaO\textsubscript{2}) due to high fractions of inspired oxygen (FiO\textsubscript{2})] following resuscitation is previously demonstrated to amplify the production of oxygen free radicals, resulting in neuronal injury and death via cellular metabolic failure and apoptosis.\textsuperscript{5,6} Current post-resuscitation guidelines recommend titrating the FiO\textsubscript{2} in post-cardiac arrest patients to avoid hypoxia, and prolonged exposure to hyperoxia (most commonly defined as PaO\textsubscript{2} > 300 mmHg).\textsuperscript{7-9} Our group previously published a retrospective registry study demonstrating an association between post-resuscitation exposure to PaO\textsubscript{2} > 300 mmHg and in-hospital mortality.\textsuperscript{10} However, subsequent observational studies examining the associations between hyperoxia and clinical outcomes have reported conflicting results.\textsuperscript{10-16} All previous studies have methodological limitations. They were mostly retrospective in nature, used varying methodologies to define PaO\textsubscript{2} derangements, and most evaluated arterial blood gas (ABG) measurements over the first 24 hours after return of spontaneous circulation (ROSC) rather than focusing on the period immediately after ROSC when the brain is likely most susceptible to additional reperfusion injury. By their design, these previous studies were subject to measurement bias, as they relied on ABG results ordered at the discretion of treating physicians, as opposed to protocol-directed ABG measurements at specific time points.
We performed a fully prospective, multi-center study using protocol-directed ABG measurements in the early hours following resuscitation and protocol directed assessments of neurological disability, as opposed to chart review. Our main objective was to test the association between early post-resuscitation hyperoxia and poor neurological outcome among adult patients successfully resuscitated from cardiac arrest.

**Methods**

**Setting**

We performed a prospective cohort study across six hospitals in the United States: 1) Cooper University Hospital, Camden, NJ (coordinating center); 2) Hospital of the University of Pennsylvania, Philadelphia, PA; 3) Penn-Presbyterian Medical Center, Philadelphia, PA; 4) Methodist Hospital, Indianapolis, IN; 5) University of Mississippi Medical Center, Jackson, MS; and 6) Beth Israel Deaconess Medical Center, Boston, MA. We prospectively collected data pertaining to the index cardiac arrest event, and outcomes consistent with the Utstein style for reporting cardiac arrest research, including all post-ROSC variables recommended for post-resuscitation research. Each of the participating centers had a mechanism in place for real-time notification of study personnel when an out-of-hospital cardiac arrest patient arrives in the emergency department (ED) or when a cardiac arrest occurs in-hospital. This study was approved by the institutional review board at each participating institution and each subject gave written informed consent. This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. After review and approval by our study data use committee, we will allow other researchers who submit to us a protocol to have unrestricted access to our complete de-identified database in comma separated value format, together with a data dictionary.

**Participants**

We enrolled adult post-cardiac arrest patients who were comatose after ROSC between July 2013 and March 2017. The inclusion criteria were: 1) age ≥ 18 years; 2) cardiac arrest, defined as a documented absence of pulse and cardiopulmonary resuscitation (CPR) initiated; 3) ROSC > 20 min; 4) mechanically ventilated after ROSC; and 5) clinician intent to perform targeted temperature management. We decided to include patients with both in- and out-of-hospital cardiac arrest, as this would generate a pragmatic study whose results could be broadly applicable to as many cardiac arrest patients as possible. We excluded patients with presumed etiology of arrest secondary to trauma, hemorrhage or sepsis; residents of a nursing home or other long-term care facility; pregnancy; prisoners; and terminal illness with no reasonable expectation to survive to hospital discharge or known lack of commitment to aggressive support by next of kin. We also excluded patients who died prior to an arterial blood gas analysis being obtained.

**Standard Care**

Routine post-cardiac arrest care across all sites consisted of standard elements recommended by the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care and included: (1) targeted temperature management for 24 hours after ROSC; (2) controlled rewarming to avoid hyperpyrexia with targeted temperature...
management; (3) 24/7 capability for goal-directed hemodynamic support interventions; (4) 24/7 capability for interventional cardiac catheterization (if needed); (5) 24/7 capability for continuous electroencephalographic monitoring; and (6) evidence-based approach to neurological prognostication, specifically waiting >72 hours after ROSC before support limitations for poor neurological prognosis.\(^7\), \(^20\)

**Data Collection**

As part of our research protocol we obtained an initial arterial blood gas (ABG) one hour (± two hours) after ROSC and a second ABG six hours (± two hours) after ROSC. At the time of ABG collection we also recorded the plateau airway pressure during an inspiratory hold on the ventilator. We recorded all additional ABG analyses ordered by the treating physician as well as all ventilator changes and the time the changes were made. The arterial oxygen saturation (SaO\(_2\)) and the fraction of inspired oxygen (FiO\(_2\)) were continuously monitored and recorded every 15 min for the initial six hours after ROSC. For both SaO\(_2\) and FiO\(_2\) the time-weighted average was calculated. To calculate the time-weighted average for each subject, we multiplied the length of time that the patient spent at a specific SaO\(_2\) value by that SaO\(_2\) value, added all these values together, and then divided by the total length of post-resuscitation observation time.\(^21\) We performed the same calculation for FiO\(_2\). We prospectively captured all the components of the Sequential Organ Failure Assessment (SOFA) score (i.e. respiratory, coagulation, hepatic, renal, cardiovascular, and neurological) during the first 24 hours after ROSC.\(^22\) For calculation of the SOFA score, we used the worst value for each component during the initial six-hour period after ROSC and excluded the neurological and respiratory components.\(^22\)–\(^24\) We abstracted clinical data from the medical record into a Research Electronic Data Capture (REDCap, Vanderbilt University, TN) database, and exported into Stata/SE 14.1 for Mac, StataCorp LP (College Station, TX, USA) for analysis.\(^25\)

**Outcome measures**

The primary outcome was poor neurological function or death at hospital discharge, defined \textit{a priori} as a modified Rankin Scale (mRS) > 3.\(^26\) The mRS is a well-validated scale of neurological disability, which is widely used to measure outcome in stroke clinical trials (0: no symptoms, 1: no significant disability, 2: slight disability, 3: moderate disability, 4: moderate severe disability, 5: severe disability, 6: death). All raters were trained and certified in mRS assessment\(^27\) and used a structured questionnaire and interview, which have been shown to produce strong interobserver reliability.\(^28\), \(^29\) Secondary outcomes were in-hospital mortality and early neurological injury defined as a Full Outline of UnResponsiveness (FOUR) score ≤ 6 at 72 hours after ROSC, based on previous literature.\(^30\), \(^31\) The FOUR score is a well-validated scale of neurological injury for comatose patients. The FOUR score has 4 components: eye responses, motor responses, brainstem reflexes, and respiration pattern, and ranges from 0 to 16 with lower scores demonstrating worse injury.\(^32\)

**Data Analysis**

Categorical variables were compared using the chi-square test. Continuous variables were compared using student t-test or Wilcoxon rank-sum test, based on the distribution of the data. We used Spearman’s correlation coefficient (\(r\)) to assess the relationship between 1-
and 6-hour PaO₂, and the corresponding FiO₂ and SaO₂. We used multivariable logistic regression analysis to identify what patient and management characteristics were associated with hyperoxia (see Supplemental Methods).

For the primary outcome, we calculated relative risk (RR) using multivariable generalized linear regression with a log link to test if exposure to hyperoxia during the initial six hours after ROSC was an independent predictor of poor neurologic function at hospital discharge. We a priori defined hyperoxia as PaO₂ > 300 mmHg on one or more ABG analyses, based on previously described definition for hyperoxia. A priori, we selected the following candidate variables for the regression model on the grounds that they were previously demonstrated to predict outcome in post–cardiac arrest patients: (1) age (decile); (2) initial cardiac rhythm [asystole or pulseless electrical activity (PEA) vs. ventricular fibrillation/pulseless ventricular tachycardia (VF/VT)]; (3) metabolic acidosis (defined as one or more recorded base deficit ≤ -6 during the initial six hours after ROSC, based on previously published literature); (4) arterial hypotension (mean arterial pressure < 70 mmHg during the initial six hours after ROSC); (5) pre-arrest comorbidities (i.e., Charlson comorbidities index); (6) prolonged duration of CPR (CPR duration > 20 min); and (7) location of cardiac arrest (in- vs. out-of-hospital). Backward elimination with a criterion of p < 0.05 for retention in the model was used. Statistical interactions and collinearity were assessed. Goodness of fit of the model was evaluated with the deviance test. This analysis was repeated for both secondary outcomes. For the main analyses listwise deletion was used for missing co-variables. We also report results using multiple imputation for missing co-variables. These models used robust standard error and took into account the random effects at the institution (i.e. site of enrollment) level.

We performed several additional pre-planned sensitivity analyses for the primary outcome. First, we entered additional covariates beyond those pre-specified into a multivariable generalized linear regression model with a log link. Second, we assessed whether cardiac arrest location (pre-hospital or in-hospital) had different results. Finally, we performed a sensitivity analysis limited to only patients who survived to hospital discharge (detailed description of sensitivity analyses is discussed in Supplemental Methods).

We also examined the association between PaO₂ and outcome across different thresholds to define hyperoxia (i.e. PaO₂ > 100, 150, 200, 250, 300, 350, and 400 mmHg on one or more ABG analyses). We entered each threshold into a multivariable generalized linear regression model with a log link and calculated relative risks with 95% confidence intervals (CI) for poor neurological outcome adjusting for candidate variables retained in the original model. We graphed the relative risks with 95% CI and inspected the graph to assess if there was a threshold signal for neurological outcome over increasing PaO₂ cut points.

To reflect the duration of hyperoxia exposure during the initial six hours after ROSC, we used the first PaO₂ measurement to represent the PaO₂ exposure during the time from ROSC to the first ABG measurement. We then calculated the time intervals between ABG measurements and inferred that the PaO₂ remained constant at the level observed in the earlier measurement until the time point of the subsequent measurement (i.e. last value carried forward). Similar methodology to estimate PaO₂ exposure has been used previously.
We then added up the total time patients had exposure to hyperoxia during the initial six hours after ROSC. To test the impact of duration of hyperoxia exposure, we entered duration of exposure as a continuous variable (calibrated for one hour) into a multivariable generalized linear regression model with a log link adjusting for the candidate variables retained in the original model. Given some subjects had ABG analyses ordered by treating physicians in addition to the protocol, we adjusted the model for the total number of ABG analyses obtained during the initial six hours after ROSC, as well as time to first ABG.

**Sample size calculation**

We estimated the necessary sample size based on the following assumptions: a) a predicted event (i.e. survival with good neurological function) rate of 29%\(^{21}\) and b) an estimated event (survival with good neurological function) per covariate ratio of 10:1 necessary for multivariable modeling.\(^{42,43}\) To accrue the necessary 80 survivors with good neurological function we estimated that a minimum of 276 total subjects would be necessary and we planned to enroll 280.

**Results**

A total of 2084 subjects were screened for inclusion and 280 were included in the final cohort (Figure 1). We were unable to obtain informed consent for 326 patients (e.g. no surrogate decision maker available or declined consent). Compared to those excluded due to lack of informed consent, the study sample had a similar mean (SD) age 59 (16) vs. 59 (15), respectively. However, we found our study sample had a higher rate of VF/VT [37% vs. 21%] and longer duration of CPR [median (IQR) 15 (8–23) vs. 10 (1–22)]. Of those included 105 (38%) had exposure to hyperoxia and 175 (62%) had no exposure to hyperoxia during the initial six hours after ROSC. The median (IQR) time from ROSC to the first ABG analysis was 59 (35–103) min and the median (IQR) number of ABG analyses during the initial six hours after ROSC was 2 (2–3).

Table 1 displays the baseline data for all subjects in the cohort, as well as for subjects with and without exposure to hyperoxia. Out-of-hospital cardiac arrest with PEA/asystole as the initial rhythm was the most common type of cardiac arrest [109/280 (39%)], followed by out-of-hospital cardiac arrest with pulseless VF/VT as the initial rhythm [86/280 (31%)]. Initial rhythm was unclear for 23 (8%) and downtime was unknown for 5 (<2%) of patients. We found no differences in age, cardiac arrest characteristics or comorbidities between those exposed and unexposed to hyperoxia. Table 2 displays post-cardiac arrest data for all subjects. All patients were mechanically ventilated and received targeted temperature management after ROSC. Percutaneous coronary intervention (PCI) was performed within the first 36 hours in 22/86 (26%) of patients with out-of-hospital, pulseless VF/VT cardiac arrest. The median (IQR) SOFA score was lower among subjects with exposure to hyperoxia [4 (2–7)] compared to those without exposure [5 (3–7)]; however, this was not found to be statistically significant (Wilcoxon rank sum test p = 0.119). We found a poor correlation between Pao\(_2\) and SaO\(_2\) (r = 0.23), as well as Pao\(_2\) and FiO\(_2\) (r = 0.27). In addition, SaO\(_2\) could not reliably rule out the presence of hyperoxia exposure, and Pao\(_2\) as high as 295 mmHg occurred with FiO\(_2\) of 0.40 (Supplemental Figures 1–3). The only management...
characteristics found to be independent predictors of hyperoxia at 0- or 6-hours were FiO₂ and PEEP, odds ratios 1.08 (95% CI 1.05–1.11) and 0.83 (95% CI 0.70–0.97) respectively (Supplemental Table 1).

Seventy percent of subjects had the primary outcome of poor neurological function or death at hospital discharge. Study subjects with exposure to hyperoxia had a higher incidence of poor neurological function at hospital discharge than patients with no exposure (77% vs. 65% respectively, absolute risk difference 12% (95% CI 1% - 23%, p = 0.035). Figure 2 displays the proportion of subjects with each mRS score stratified by hyperoxia exposure (yes/no). The overall in-hospital mortality for the entire cohort was 55%. The mortality rate was 59% versus 52% among those with and without hyperoxia exposure respectively (p = 0.251). Two hundred and twenty five subjects survived to 72 hours and had a FOUR score measurement. The median (IQR) FOUR score at 72 hours was 8 (3–13) for the entire cohort, and 7 (3–13) vs. 10 (4–13) among patients with and without hyperoxia respectively (Wilcoxon rank sum test p = 0.148). Forty-seven percent vs. 35% had early neurological injury at 72 hours among patients with and without hyperoxia respectively (p = 0.073). The FOUR score among those who died after 72 hours was significantly lower compared to those who survived to hospital discharge [3 (0–7) vs. 13 (10–16) Wilcoxon rank sum test p < 0.001], suggesting those who died had significant neurological injury prior to death.

Table 3 displays the results of the multivariable regression models for the primary outcome as well as both secondary outcomes. After adjusting for potential baseline and post-cardiac arrest confounders, hyperoxia was an independent predictor of poor neurological function at hospital discharge, relative risk 1.23 (95% CI 1.11 - 1.35), as well as early neurological injury. Hyperoxia was found to be associated with in-hospital mortality when multiple imputation was used (see Supplemental Tables 2–7 for results of the full regression models).

For the first sensitivity analysis of the primary outcome, several variables were statistically different at p < 0.10 when comparing hyperoxia and no hyperoxia groups: gender, mean positive end expiratory pressure (PEEP), plateau airway pressure > 30 cmH₂O, time-weighted average SaO₂, time from ROSC to first ABG analysis, and mean PaCO₂ during the initial six hours after ROSC. After adjusting for these identified potential confounders, hyperoxia remained an independent predictor of poor neurological outcome, relative risk 1.23 (95% CI 1.05–1.44) (Supplemental Table 8). We did not find evidence that the association between hyperoxia and poor neurological outcome differed between cardiac arrest locations (Supplemental Table 9). Among patients who survived to hospital discharge, 33% had poor neurological outcome at hospital discharge. Hyperoxia remained an independent predictor of poor neurological outcome among survivors to hospital discharge, relative risk 1.42 (95% CI 1.09–1.87) (Supplemental Table 10).

Figure 3 displays adjusted relative risks with 95% CI for poor neurological outcome across ascending cut points used to define hyperoxia. Only PaO₂ cut points of 300 mmHg and greater were found to be significantly associated with poor neurological outcome.

During the initial six hours after ROSC, after adjusting for potential baseline and post-cardiac arrest confounders and total number of ABG analyses, a one-hour longer duration of
hyperoxia exposure was associated with a 3% increase in risk of poor neurological outcome [relative risk 1.03 (95% CI 1.02 - 1.05)] (Supplemental Table 11).

**Discussion**

In this prospective, multi-center study, using a standardized protocol for ABG measurements, we tested whether exposure to hyperoxia after resuscitation from cardiac arrest was associated with poor neurological function at hospital discharge. We found 38% of patients had exposure to hyperoxia during the early hours following resuscitation, and that hyperoxia exposure after ROSC was an independent predictor of poor neurological function at hospital discharge. Our results suggest that the association between supranormal levels of PaO$_2$ and poor neurological outcome begins at a PaO$_2$ of 300 mmHg and higher. In addition, we found an association between duration of hyperoxia exposure and neurological outcome. In our multivariable models we also found hyperoxia to be independently associated with early neurological injury and our results suggest hyperoxia is associated with in-hospital mortality. Early neurological injury was common among subjects who died in hospital, suggesting that neurological injury was a major factor for mortality. Thus, it is reasonable to infer that hyperoxia’s association with mortality is mediated by early neurological injury. Finally, we found that SaO$_2$ and FiO$_2$ levels could not reliably rule out exposure to hyperoxia; therefore, frequent ABG measurements may be needed to avoid hyperoxia exposure. Although we found a weak correlation between FiO$_2$ and PaO$_2$ on univariable analysis, when adjusted for other ventilator settings and patient characteristics we found higher FiO$_2$ was a predictor of hyperoxia exposure. We also found higher PEEP to have a negative association with hyperoxia exposure. Higher PEEP strategies are often employed in patients with lung injury who have higher oxygen requirements. Thus, elevated PEEP may be a marker for patients who are more difficult to oxygenate and thus less likely to develop hyperoxia. In summary, in this prospective, multi-center study using protocol-directed ABG measurements, we found that hyperoxia during the early period after ROSC is associated with poor neurological outcome.

Hyperoxia is postulated to cause harm in the context of reperfusion injury by increasing the formation of reactive oxygen species resulting in oxidative impairment of mitochondrial respiration and cerebral energy metabolism. Oxidative modification of mitochondrial proteins may disable brain pyruvate dehydrogenase complex activity, the only bridge between anaerobic and aerobic metabolism. In addition, oxidative stress activates the mitochondrial permeability transition pore to release NAD(H) into the cytosol, depleting a vital metabolic cofactor. Metabolic failure may ensue, resulting in decreased cerebral consumption of glucose and oxygen, increased production of lactate, and delayed neuronal cell death. Furthermore, increased reactive oxygen species may impair electron transport chain activity by forming mitochondrial membrane pores that release cytochrome $c$ into the cytosol, resulting in caspase-dependent apoptosis. Increased reactive oxygen species may also cause oxidation of brain lipids (i.e. lipid peroxidation), which may have physiologic (e.g. alteration of blood flow, neutrophil chemoattraction) and cellular toxic effects (e.g. excitotoxicity, neurodegeneration), as well as promote cellular inflammatory reactions, specifically the activation of microglia and astrocytes in the neuronal microenvironment leading to increased neuronal cell death. Additionally,
hyperoxia may also have a direct vasoconstrictor effect, which may reduce cerebral blood flow after ROSC, exacerbating ischemic injury.51, 52

Preclinical studies support the hypothesis that hyperoxia after ROSC worsens brain damage, as evidenced on functional neurological testing48, 50, 53 and histopathology,47, 54 and decreases survival.49 A recent randomized clinical trial of patients with acute myocardial infarction found no decrease in mortality at one year with the use of supplemental oxygen compared to room air.55 In addition, a randomized clinical trial of supplemental oxygen versus no supplemental oxygen in patients with ST-elevation myocardial infarction found supplemental oxygen increased the risk of recurrent myocardial infarction and cardiac arrhythmias, and increased myocardial infarct size at six months, suggesting higher PaO2 levels worsen myocardial reperfusion injury.56

Current post-resuscitation guidelines recommend that if the SaO2 is greater than 98% during the early period after cardiac arrest, the FiO2 should be titrated down to avoid prolonged exposure to hyperoxia.7–9 However, the current data on hyperoxia after resuscitation from cardiac arrest have significant limitations and are mostly from retrospective cohort studies, with conflicting results.10–16, 57, 58 Interpreting the current literature is difficult secondary to heterogeneity in methodologies used to define PaO2 derangements and outcomes. In addition, none of these previous studies used protocol-directed ABG measurements at specific time points causing concern for measurement bias. A recent systematic review and meta-analysis of observational studies found hyperoxia to be associated with in-hospital mortality; however, the authors of this meta-analysis warn these results should be interpreted with caution as there was significant heterogeneity between studies.59

A recent cohort study with historical controls found that initiating conservative oxygen therapy targeting a SaO2 of 88–92% using the lowest possible FiO2 among post-cardiac arrest patients admitted to the intensive care unit, was feasible and decreased ICU length of stay, but did not improve survival to hospital discharge.60 Of note, all patients in both the titrated and the conventional oxygen therapy groups in this previous study had PaO2 levels less than 200 mmHg, thus these results do not help inform the effects of PaO2 above 200 mmHg. To date there have been two randomized control trials evaluating the effects of supranormal PaO2 levels after resuscitation from cardiac arrest. One study randomized 28 subjects to a FiO2 of 0.30 versus 1.0 and found conservative oxygen therapy was safe.61 This trial found no difference in serum neuron specific enolase (NSE), a marker of neuronal injury, in the entire cohort, but found use of 0.30 oxygen was associated with decreased level of NSE at 24 hours in patients not treated with targeted temperature management. A second study in the pre-hospital setting randomized 18 subjects to standard care (highest possible oxygen flow rate) versus oxygen titration (targeting SaO2 90–94%).62 This trial was terminated early due to increased hypoxia episodes in the oxygen titration group. These data suggest titration of FiO2 is perhaps more appropriately managed in the hospital setting.

The results in this current study prospectively validate our previous findings that a PaO2 > 300 mmHg is associated with poor clinical outcomes.10 These findings, in conjunction with the current body of literature evaluating the association between PaO2/supplemental oxygen and clinical outcomes during reperfusion injury, support current post-cardiac arrest guideline
recommendations to avoid prolonged exposure to hyperoxia. This study has important implications for future design of clinical trials aimed at identifying an optimal PaO$_2$ after ROSC. Specifically, given the current evidence of an association with harm, and no evidence to suggest any potential benefit, such trials should focus on testing varying PaO$_2$ ranges below 300 mmHg, as at this time there is currently insufficient equipoise to ethically randomize subjects to a PaO$_2$ > 300 mmHg.

We acknowledge that this study has important limitations to consider. First, this was an observational study and thus we can only report association rather than infer causation. Second, although we used multivariable linear regression with a log link and multiple sensitivity analyses to adjust for potential confounders, there still exists the potential of unmeasured confounders. Third, in contrast to some resuscitation clinical investigations we included patients with both in- and out-of-hospital cardiac arrest. We felt this was necessary to allow for a more pragmatic study, in which the results can be applicable to the largest possible patient population. In the present study, arrest location was not associated with outcome. In addition, on sensitivity analysis we did not find evidence that the association between hyperoxia and poor neurological outcome differs between arrest locations (i.e. arrest location was not an effect modifier). Fourth, 326 subjects were excluded secondary to inability to obtain informed consent. Although we found similar mean ages between our study sample and those subjects excluded due to lack of informed consent, we found our study population had a higher rate of VT/VF and longer duration of CPR, suggesting some difference between our study sample and those excluded due to lack of informed consent, potentially introducing selection bias. Of note, 29% of subjects screened for inclusion who underwent CPR for cardiac arrest were excluded secondary to known lack of commitment to aggressive support. These patients likely underwent CPR secondary to the treatment team being unaware of the patient’s wishes (i.e. unavailable or no advanced directive) or family made the decision to withdraw care shortly after ROSC. Fifth, we found discordance between the measured PaO$_2$ and corresponding SaO$_2$. This discordance is likely secondary to poor SaO$_2$ sensing, and demonstrates the limitations of pulse oximetry and underscores the importance of obtaining an ABG for PaO$_2$ monitoring. Sixth, for estimating the duration of hyperoxia exposure we assumed the PaO$_2$ level remained constant between ABG analyses. It is possible that the PaO$_2$ level varied during this time allowing for potential measurement bias. Finally, it remains possible that hyperoxia reflects a patient population that is more ill and therefore has a higher likelihood to have poor neurological outcome. However, we did not observe any significant differences in the duration of CPR, post-resuscitation SOFA score, incidence of post-resuscitation arterial hypotension or vasopressor administration, or degree of metabolic acidosis between the two groups, suggesting this was not the case.

**Conclusion**

Early hyperoxia exposure after resuscitation from cardiac arrest is independently associated with death and poor neurological function at hospital discharge. The increased risk of poor neurological function appears to begin at a PaO$_2$ of 300 mmHg.
Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding sources

National Heart, Lung, and Blood Institute (U.S.), R01HL112815. The funding source had no role in study design, in collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.

References


Clinical Perspective

What’s new

• In this prospective multi-center protocol-directed cohort study that included 280 adult post-cardiac arrest patients, early hyperoxia exposure [partial pressure of arterial oxygen (PaO$_2$) > 300 mmHg during the first six hours after return of spontaneous circulation (ROSC)] was an independent predictor of poor neurological function at hospital discharge after adjusting for potential baseline and post-cardiac arrest confounders, relative risk 1.23 (95% CI 1.11 - 1.35).

What are the clinical implications

• Early hyperoxia exposure after resuscitation from cardiac arrest is independently associated with death and poor neurological function at hospital discharge. The increased risk of poor neurological function appears to begin at a PaO$_2$ of 300 mmHg.
2084 post-cardiac arrest patients assessed for eligibility

1804 excluded from analysis

- 609 Following commands immediately after ROSC
- 597 Terminal illness with no reasonable expectation of survival to hospital discharge or known lack of commitment to aggressive support
- 326 Unable to obtain informed consent
- 66 Permanent resident of long term care facility

Etiology of arrest

- 55 Trauma
- 51 Hemorrhage
- 81 Sepsis

- 12 No arterial blood gas in the first six hours after ROSC
- 6 Prisoner
- 1 Pregnancy

280 patients included in the final analysis

Figure 1.
Study flow diagram
ROSC, return of spontaneous circulation
Figure 2.
Modified Rankin Scale at hospital discharge stratified by no hyperoxia (gray columns) and hyperoxia (black columns).
mRS: 0, no symptoms; 1, no significant disability; 2, slight disability; 3, moderate disability; 4, moderate severe disability; 5, severe disability; 6, death
Figure 3.
Adjusted relative risks (squares) with 95% confidence intervals (horizontal lines) for poor neurological outcome [defined as modified Rankin Scale (mRS) > 3] across ascending cut points to define hyperoxia.

*Relative risks were calculated using multivariable linear regression analysis (with a log link) adjusting for age, initial cardiac rhythm, metabolic acidosis, arterial hypotension, pre-arrest comorbidities, and prolonged duration of cardiopulmonary resuscitation.

<table>
<thead>
<tr>
<th>Cut point</th>
<th>No Hyperoxia n (Proportion with mRS &gt; 3)</th>
<th>Hyperoxia n (Proportion with mRS &gt;3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>40 (60%)</td>
<td>240 (71%)</td>
</tr>
<tr>
<td>150</td>
<td>77 (64%)</td>
<td>203 (72%)</td>
</tr>
<tr>
<td>200</td>
<td>114 (67%)</td>
<td>166 (72%)</td>
</tr>
<tr>
<td>250</td>
<td>139 (66%)</td>
<td>141 (73%)</td>
</tr>
<tr>
<td>300</td>
<td>175 (65%)</td>
<td>105 (77%)</td>
</tr>
<tr>
<td>350</td>
<td>199 (65%)</td>
<td>81 (80%)</td>
</tr>
<tr>
<td>400</td>
<td>216 (67%)</td>
<td>64 (78%)</td>
</tr>
<tr>
<td>Variables</td>
<td>All Subjects n = 280</td>
<td>No Hyperoxia n = 175</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Age [years (SD)]</td>
<td>59 (15)</td>
<td>59 (14)</td>
</tr>
<tr>
<td>Female [n (%)]</td>
<td>101 (36)</td>
<td>70 (40)</td>
</tr>
<tr>
<td>Pre-existing comorbidities [n (%)]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>68 (24)</td>
<td>42 (24)</td>
</tr>
<tr>
<td>Known coronary artery disease</td>
<td>75 (27)</td>
<td>49 (28)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>183 (65)</td>
<td>120 (69)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>20 (7)</td>
<td>14 (8)</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>43 (15)</td>
<td>26 (15)</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>65 (23)</td>
<td>39 (22)</td>
</tr>
<tr>
<td>Cerebral vascular disease</td>
<td>24 (9)</td>
<td>17 (10)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>69 (25)</td>
<td>42 (24)</td>
</tr>
<tr>
<td>Charlson comorbidity score&lt;sup&gt;36&lt;/sup&gt; [median (IQR)]</td>
<td>1 (0–3)</td>
<td>1 (0–3)</td>
</tr>
<tr>
<td>Arrest location [n (%)]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Out-of-hospital</td>
<td>216 (77)</td>
<td>138 (79)</td>
</tr>
<tr>
<td>In-hospital</td>
<td>64 (23)</td>
<td>37 (21)</td>
</tr>
<tr>
<td>Initial arrest rhythm [n (%)]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEA/asystole</td>
<td>154 (55)</td>
<td>92 (53)</td>
</tr>
<tr>
<td>VF/VT</td>
<td>103 (37)</td>
<td>66 (37)</td>
</tr>
<tr>
<td>Unknown</td>
<td>23 (8)</td>
<td>17 (10)</td>
</tr>
<tr>
<td>CPR duration [median (IQR)]</td>
<td>15 (8–23)</td>
<td>15 (7–25)</td>
</tr>
<tr>
<td>CPR duration &gt; 20 min [n (%)]</td>
<td>80 (29)</td>
<td>54 (31)</td>
</tr>
</tbody>
</table>

* Partial pressure of arterial oxygen > 300 mmHg during the first six hours after return of spontaneous circulation; CPR, cardiopulmonary resuscitation; IQR, interquartile range; PEA, pulseless electrical activity; SD, standard deviation; VF, ventricular fibrillation; VT ventricular tachycardia
Table 2

Post-cardiac arrest data for all subjects. All values are median interquartile range unless otherwise noted.

<table>
<thead>
<tr>
<th>Variables</th>
<th>All Subjects n = 280</th>
<th>No Hyperoxia n = 175</th>
<th>Hyperoxia* n = 105</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventilator parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TWA-FiO₂</td>
<td>0.82 (0.66–0.97)</td>
<td>0.87 (0.64–0.99)</td>
<td>0.78 (0.68–0.92)</td>
<td>0.162</td>
</tr>
<tr>
<td>PEEP (cmH₂O)</td>
<td>5 (5–7)</td>
<td>5 (5–8)</td>
<td>5 (5–5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tidal volume (cc/kg PBW)</td>
<td>7.4 (6.7–8.1)</td>
<td>7.4 (6.8–8.1)</td>
<td>7.3 (6.7–8.0)</td>
<td>0.537</td>
</tr>
<tr>
<td>Respiratory rate (breaths/min)</td>
<td>17 (15–20)</td>
<td>17 (15–21)</td>
<td>16 (15–20)</td>
<td>0.282</td>
</tr>
<tr>
<td>Plateau pressure (cmH₂O)</td>
<td>20 (16–25)</td>
<td>21 (17–26)</td>
<td>20 (16–23)</td>
<td>0.241</td>
</tr>
<tr>
<td>Plateau pressure &gt; 30 cmH₂O [n (%)]</td>
<td>42 (18)</td>
<td>33 (22)</td>
<td>9 (10)</td>
<td>0.016</td>
</tr>
<tr>
<td>PaO₂ at 1 hr</td>
<td>201 (99–343)</td>
<td>121 (82–203)</td>
<td>406 (304–488)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PaO₂ at 6 hr</td>
<td>106 (75–193)</td>
<td>99 (71–156)</td>
<td>128 (88–238)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TWA-SaO₂ (%)</td>
<td>98 (97–99)</td>
<td>98 (96–99)</td>
<td>99 (98–100)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ROSC to first ABG (min)</td>
<td>59 (35–103)</td>
<td>63 (39–122)</td>
<td>48 (28–76)</td>
<td>0.002</td>
</tr>
<tr>
<td>Number of ABGs in first 6 hours</td>
<td>2 (2–3)</td>
<td>2 (2–3)</td>
<td>3 (2–3)</td>
<td>0.173</td>
</tr>
<tr>
<td>PaCO₂ (mmHg)</td>
<td>44 (37–52)</td>
<td>45 (38–54)</td>
<td>43 (36–50)</td>
<td>0.077</td>
</tr>
<tr>
<td>pH</td>
<td>7.27 (7.18–7.34)</td>
<td>7.26 (7.18–7.34)</td>
<td>7.28 (7.20–7.35)</td>
<td>0.160</td>
</tr>
<tr>
<td>Base excess</td>
<td>–8 (-11–0)</td>
<td>–8 (-12–4)</td>
<td>–6 (-10–3)</td>
<td>0.256</td>
</tr>
<tr>
<td>Metabolic acidosis † [n (%)]</td>
<td>202 (72)</td>
<td>128 (73)</td>
<td>74 (70)</td>
<td>0.630</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>94 (82–105)</td>
<td>93 (81–103)</td>
<td>95 (84–106)</td>
<td>0.209</td>
</tr>
<tr>
<td>Arterial hypotension ‡ [n (%)]</td>
<td>142 (51)</td>
<td>95 (54)</td>
<td>47 (45)</td>
<td>0.123</td>
</tr>
<tr>
<td>Vasopressor infusion [n (%)]</td>
<td>150 (54)</td>
<td>99 (57)</td>
<td>51 (49)</td>
<td>0.194</td>
</tr>
<tr>
<td>PCI [n (%)]</td>
<td>31 (11)</td>
<td>20 (11)</td>
<td>11 (10)</td>
<td>0.806</td>
</tr>
<tr>
<td>Modified SOFA score</td>
<td>5 (2–7)</td>
<td>5 (3–7)</td>
<td>4 (2–7)</td>
<td>0.119</td>
</tr>
</tbody>
</table>

* Partial pressure of arterial oxygen > 300 mmHg during the first six hours after return of spontaneous circulation.
† Defined as a base deficit ≤ −6 during the first 6 hours after return of spontaneous circulation.
‡ Defined as mean arterial pressure < 70 mmHg during the first 6 hours after return of spontaneous circulation. ABG, arterial blood gas; FiO₂, fraction of inspired oxygen; MAP, mean arterial blood pressure; PaCO₂, partial pressure of arterial carbon dioxide; PBW, predicted body weight; PCI, percutaneous coronary intervention; PEEP, positive end expiratory pressure, ROSC, return of spontaneous circulation; SaO₂, arterial oxygen saturation; SOFA, sequential organ failure assessment; TWA, time weighted average.
Table 3

Adjusted relative risks for hyperoxia (partial pressure of arterial oxygen > 300 mmHg) for the primary and secondary outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Relative Risk</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Outcome:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor Neurological Outcome *</td>
<td>1.23</td>
<td>1.11–1.35</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Listwise deletion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple imputation</td>
<td>1.24</td>
<td>1.13–1.35</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Secondary Outcomes:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In-hospital mortality</td>
<td>1.24</td>
<td>0.99–1.55</td>
<td>0.060</td>
</tr>
<tr>
<td>Listwise deletion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple imputation</td>
<td>1.25</td>
<td>1.01–1.54</td>
<td>0.040</td>
</tr>
<tr>
<td>Early neurological injury †</td>
<td>1.32</td>
<td>1.03–1.69</td>
<td>0.026</td>
</tr>
<tr>
<td>Listwise deletion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple imputation</td>
<td>1.39</td>
<td>1.11–1.74</td>
<td>0.004</td>
</tr>
</tbody>
</table>

* Defined as modified Rankin Scale (mRS) > 3 at hospital discharge;
† Defined as a Full Outline of UnResponsiveness (FOUR) score ≤6 at 72 hours after return of spontaneous circulation. CI, confidence interval. Results of the full models are displayed in the supplemental material.